Public disclosures

Goncalves Joana

Company insiders · Chief Medical Officer · Oruka Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-16.Following & alerts
Reported transaction lines
10
Buy lines
0
Sell lines
6

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-1110

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Employee Warrant (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 157992 · The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

2026-11-162026-11-16

3,500 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 186563 · The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

2026-11-162026-11-16

3,500 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 31771 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.48 to $106.20, inclusive.

2026-11-162026-11-16

≈ $52,928.00

500 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 32271 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.26 to $103.46, inclusive.

2026-11-162026-11-16

≈ $20,672.00

200 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 32471 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.18 to $102.95, inclusive.

2026-11-162026-11-16

≈ $30,741.00

300 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 32771 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.11 to $102.09, inclusive.

2026-11-162026-11-16

≈ $192,900.92

1,900 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 34671 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.04, inclusive.

2026-11-162026-11-16

≈ $150,718.80

1,500 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 36171 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.03 to $99.98, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.

2026-11-162026-11-16

≈ $258,739.00

2,600 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 38771

2026-11-162026-11-16

3,500 shares/units

SEC 4
Goncalves Joana

Chief Medical Officer · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 35271

2026-11-162026-11-16

3,500 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement